Elevated plasma homocysteine levels: Risk factor or risk marker for the development of dementia and Alzheimer's disease?

Journal of Alzheimer's Disease

Volumn 9, Issue 4, 2006, Pages 393-398

  Seshadri, Sudha ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Dementia; Homocysteine; Plasma; Risk factor

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

AGING; ALZHEIMER DISEASE; BLOOD LEVEL; COGNITION; DEMENTIA; DISEASE MARKER; HEART INFARCTION; HUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE;

EID: 33747391975     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2006-9404     Document Type: Review

References (67)

1. W.B. Kannel, T.R. Dawber, A. Kagan, N. Revotskie and J.I. Stokes, Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Study, Ann Intern Med 55 (July, 1961), 33-50.
2. M. Hanefeld and K. Luthke, Hypertriglyceridemia-independent risk factor or risk marker? Przegl Lek 46(7) (1989), 588-594.
3. R.K. Nadella, Risk marker for Wernicke's encephalopathy, Lancet 1(8130) (23 June, 1979), 1354.
4. T. Gerritsen, J.G. Vaughn and H.A. Waisman, The identification of homocystine in the urine. Biochem Biophys Res Commun 9 (19 December 1962), 493-496.
5. N.A. Carson, D.C. Cusworth, C.E. Dent, C.M. Field, D.W. Neill and R.G. Westall, Homocystinuria: A new inborn error of metabolism associated with mental deficiency, Arch Dis Child 38 (October 1963), 425-436.
6. K.S. McCully, Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis, Am J Pathol 56(1) (July 1969), 111-128.
7. A.G. Bostom, I.H. Rosenberg, H. Silbershatz et al., Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study, Ann Intern Med 131(5) (7 September 1999), 352-355.
8. A.G. Bostom, H. Silbershatz, I.H. Rosenberg et al., Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women, Arch Intern Med 159(10) (24 May 1999), 1077-1080.
9. J. Lindenbaum, E.B. Healton, D.G. Savage et al., Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis, N Engl J Med 318(26) (30 June 1988), 1720-1728.
10. A. Hofman, A. Ott, M.M. Breteler et al., Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study, Lancet 349(946) (18 January 1997), 151-154.
11. D.A. Snowdon, L.H. Greiner, J.A. Mortimer, K.P. Riley, P.A. Greiner and W.R. Markesbery, Brain infarction and the clinical expression of Alzheimer disease, The Nun Study, JAMA 277(10) (12 March 1997), 813-817.
12. R. Clarke, A.D. Smith, K.A. Jobst, H. Refsum, L. Sutton and P.M. Ueland, Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease, Arch Neurol 55(11) (November 1998), 1449-1455.
13. C.G. Gottfries, W. Lehmann and B. Regland, Early diagnosis of cognitive impairment in the elderly with the focus on Alzheimer's disease, J Neural Transm 105(8-9) (1998), 773-786.
14. M.S. Morris, P.F. Jacques, I.H. Rosenberg and J. Selhub, Hyperhomocysteinemia associated with poor recall in the third National Health and Nutrition Examination Survey, American Journal of Clinical Nutrition 73(5) (May 2001), 927-933.
15. N.D. Prins, T. den Heijer, A. Hofman et al., Homocysteine and cognitive function in the elderly - The Rotterdam Scan Study, Neurology 59(9) (12 November 2002), 1375-1380.
16. A. McCaddon, G. Davies, P. Hudson, S. Tandy and H. Cattell, Total serum homocysteine in senile dementia of Alzheimer type, Int J Geriatr Psychiatry 13(4) (April 1998), 235-239.
17. A.B. Hill, The Enironment and Disease: Association or Causation? Proc R Soc Med 58 (May 1965), 295-300.
18. S. Seshadri, A. Beiser, J. Selhub et al., Plasma homocysteine as a risk factor for dementia and Alzheimer's disease, New England Journal of Medicine 346(7) (14 February 2002), 476-483.
19. G. Ravaglia, P. Forti, F. Maioli et al., Homocysteine and folate as risk factors for dementia and Alzheimer disease, Am J Clin Nutr 82(3) (September 2005), 636-643.
20. J.A. Luchsinger, M.X. Tang, S. Shea, J. Miller, R. Green and R. Mayeux, Plasma homocysteine levels and risk of Alzheimer disease, Neurology 62(11) (8 June 2004), 1972-1976.
21. M.F. Elias, L.M. Sullivan, R.B. D'Agostino et al., Homocysteine and cognitive performance in the Framingham offspring study: age is important, Am J Epidemiol 162(7) (1 October 2005), 644-653.
22. G. Ravaglia, P. Forti, F. Maioli et al., Homocysteine and cognitive performance in healthy elderly subjects, Arch Gerontol Geriatr Suppl (9) (2004), 349-357.
23. J.H. Schafer, T.A. Glass, K.I. Bolla, M. Mintz, A.E. Jedlicka and B.S. Schwartz, Homocysteine and cognitive function in a population-based study of older adults, J Am Geriatr Soc 53(3) (March 2005), 381-388.
24. C.B. Wright, M.C. Paik, T.R. Brown et al., Total homocysteine is associated with white matter hyperintensity volume: the Northern Manhattan Study, Stroke 36(6) (June 2005), 1207-1211.
25. W.T. Longstreth, Jr., R. Katz, J. Olson et al., Plasma total homocysteine levels and cranial magnetic resonance imaging findings in elderly persons: the Cardiovascular Health Study, Arch Neurol 61(1) (January 2004), 67-72.
26. H.T. Den, S.E. Vermeer, R. Clarke et al., Homocysteine and brain atrophy on MRI of non-demented elderly, Brain 126(Pt 1) (January 2003), 170-175.
27. J.H. Williams, E.A. Pereira, M.M. Budge and K.M. Bradley, Minimal hippocampal width relates to plasma homocysteine in community-dwelling older people, Age Ageing 31(6) (November 2002), 440-444.
28. T. Matsui, H. Arai, T. Yuzuriha et al., Elevated plasma homocysteine levels and risk of silent brain infarction in elderly people, Stroke 32(5) (May 2001), 1116-1119.
29. D. Xu, R. Neville and T. Finkel, Homocysteine accelerates endothelial cell senescence, FEBS Lett 470(1) (17 March 2000), 20-24.
30. J. Stessman, Y. Maaravi, R. Hammerman-Rozenberg et al., Candidate genes associated with ageing and life expectancy in the Jerusalem longitudinal study, Mech Ageing Dev 126(2) (February 2005), 333-339.
31. P.I. Ho, D. Ortiz, E. Rogers and T.B. Shea, Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage, J Neurosci Res 70(5) (1 December 2002), 694-702.
32. I.I. Kruman, T.S. Kumaravel, A. Lohani et al., Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease, J Neurosci 22(5) (1 March 2002), 1752-1762.
33. B. Benz, G. Grima and K.Q. Do, Glutamate-induced homocysteic acid release from astrocytes: possible implication in glia-neuron signaling, Neuroscience 124(2) (2004), 377-386.
34. J. Lehmann, C. Tsai and P.L. Wood, Homocysteic acid as a putative excitatory amino acid neurotransmitter: I. Postsynaptic characteristics at N-methyl-D-aspartate-type receptors on striatal cholinergic interneurons, J Neurochem 51(6) (December 1998), 1765-1770.
35. H. Jakubowski, Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels, FASEB J 13(15) (December 1999), 2277-2283.
36. M. Medina, J.L. Urdiales and M.I. Mores-Sanchez, Roles of homocysteine in cell metabolism: old and new functions, Eur J Biochem 268(14) (July 2001), 3871-3882.
37. E.L. Streck, A.I. Zugno, B. Tagliari, C. Wannmacher, M. Wajner and A.T. Wyse, Inhibition of Na+, K+-ATPase activity by the metabolites accumulating in homocystinuria, Metab Brain Dis 17(2) (June 2002), 83-91.
38. E.L. Streck, C. Matte, P.S. Vieira et al., Impairment of energy metabolism in hippocampus of rats subjected to chemically-induced hyperhomocysteinemia, Biochim Biophys Acta 1637(3) (17 April 2003), 187-192.
39. X. Sai, Y. Kawamura, K. Kokame et al., Endoplasmic reticulum stress-inducible protein, Herp, enhances presenilin-mediated generation of amyloid beta-protein, J Biol Chem 277(15) (12 April 2002), 12915-12920.
40. A.R. White, X. Huang, M.F. Jobling et al., Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways, J Neurochem 76(5) (March 2001), 1509-1520.
41. S.B. Vafai and J.B. Stock, Protein phosphatase 2A methylation: a link between elevated plasma homocysteine and Alzheimer's Disease, FEBS Lett 518(1-3) (8 May 2002), 1-4.
42. G.N. Welch and J. Loscalzo, Homocysteine and atherothrombosis, N Engl J Med 338(15) (9 April 1998), 1042-1050.
43. J.M. Kim, H. Lee and N. Chang, Hyperhomocysteinemia due to short-term folate deprivation is related to electron microscopic changes in the rat brain, J Nutr 132(11) (November 2002), 3418-3421.
44. M.S. Morris, Homocysteine and Alzheimer's disease, Lancet Neurol 2(7) (July 2003), 425-428.
45. K. Nilsson, L. Gustafson and B. Hultberg, Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine, Int J Geriatr Psychiatry 16(6) (June 2001), 609-614.
46. J.F. Toole, M.R. Malinow, L.E. Chambless et al., Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial, JAMA 291(5) (4 February 2004), 565-575.
47. K.H. Bonaa, I. Njolstad, P.M. Ueland et al., Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction, N Engl J Med (12 March 2006), NEJMoa055227.
48. The Heart Outcomes Prevention Evaluation (HOPE). Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease, N Engl J Med (12 March 2006), NEJMoa060900.
49. Q. Yang, L.D. Botto, J.D. Erickson et al., Improvement in stroke mortality in Canada and the United States, 1990 to 2002, Circulation 113(10) (14 March 2006), 1335-1343.
50. L.A. Bazzano, J. He, L.G. Ogden et al., Dietary intake of folate and risk of stroke in US men and women: NHANES I Epidemiologic Follow-up Study. National Health and Nutrition Examination Survey, Stroke 33(5) (May 2002), 1183-1188.
51. N. Weiss, R. Hilge and U. Hoffmann, Mild hyperhomocysteinemia: risk factor or just risk predictor for cardiovascular diseases? Vasa 33(4) (November 2004), 191-203.
52. J. Loscalzo, Homocysteine Trials - Clear Outcomes for Complex Reasons, N Engl J Med (14 March 2006).
53. A. McCaddon, B. Regland, P. Hudson and G. Davies, Functional vitamin B(12) deficiency and Alzheimer disease, Neurology 58(9) (14 May 2002), 1395-1399.
54. D. Santiard-Baron, J. Aupetit and N. Janel, Plasma homocysteine levels are not increased in murine models of Alzheimer's disease, Neurosci Res 53(4) (December 2005), 447-449.
55. J. Pacheco-Quinto, E.B. Rodriguez de Turco, S. Derosa et al., Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels, Neurobiol Dis (2 March 2006).
56. J.D. Spence, V.J. Howard, L.E. Chambless et al., Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design, Neuroepidemiology 20(1) (February 2001), 16-25.
57. The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke, Cerebrovasc Dis 13(2) (2002), 120-126.
58. P.S. Aisen, S. Egelko, H. Andrews et al., A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease, Am J Geriatr Psychiatry 11(2) (March 2003), 246-249.
59. M. Malouf, E.J. Grimley and S.A. Areosa, Folic acid with or without vitamin B12 for cognition and dementia, Cochrane Database Syst Rev (4) (2003), CD004514.
60. M.F. Elias, A. Beiser, P.A. Wolf, R. Au, R.F. White and R.B. D'Agostino, The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort, Arch Neurol 57(6) (June 2000), 808-813.
61. Y. Shah, E.G. Tangalos and R.C. Petersen, Mild cognitive impairment. When is it a precursor to Alzheimer's disease? Geriatrics 55(9) (September 2000), 62, 65-2, 68.
62. S. Annerbo, L.O. Wahlund and J. Lokk, The relation between homocysteine levels and development of Alzheimer's disease in mild cognitive impairment patients, Dement Geriatr Cogn Disord 20(4) (2005), 209-214.
63. R. Clarke, G. Harrison and S. Richards, Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia, J Intern Med 254(1) (July 2003), 67-75.
64. D.J. Stott, G. Macintosh, G.D. Lowe et al., Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease, American Journal of Clinical Nutrition 82(6) (1 December 2005), 1320-1326.
65. J. Van Uffelen, M. Hopman-Rock, A.P. Chin and W. Van Mechelen, Protocol for Project FACT: a randomised controlled trial on the effect of a walking program and vitamin B supplementation on the rate of cognitive decline and psychosocial wellbeing in older adults with mild cognitive impairment [ISRCTN19227688], BMC Geriatrics 5(1) (2005), 18.
66. J.A. McMahon, T.J. Green, C.M. Skeaff, R.G. Knight, J.I. Mann and S.M. Williams, A controlled trial of homocysteine lowering and cognitive performance, N Engl J Med 354(26) (29 June 2006), 2764-2772.
67. R. Clarke, Vitamin B12, folic acid, and the prevention of dementia, N Engl J Med 354(26) (29 June 2006), 2817-2819.